Rystiggo received FDA approval on June 20, 2023 [1].
When can Rystiggo be prescribed?
Rystiggo is approved for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody-positive [1].
What is Rystiggo and how does it work?
Rystiggo is a systemic, targeted, symptom-reducing therapy that targets the neonatal Fc receptor (FcRn) [1]. By inhibiting the FcRn, Rystiggo reduces the levels of pathogenic immunoglobulin G (IgG) autoantibodies [1]. In patients with gMG, these antibodies attack the neuromuscular junction, disrupting communication between nerves and muscles [1].
Are there other treatments for myasthenia gravis?
Yes, various treatment options exist for myasthenia gravis, including immunosuppressants, plasma exchange, and intravenous immunoglobulin [2]. Rystiggo offers a new therapeutic approach by targeting the underlying mechanism of IgG autoantibody production.
What are the potential side effects of Rystiggo?
Common side effects reported in clinical trials for Rystiggo include upper respiratory tract infection and headache [1].
How effective is Rystiggo?
In clinical trials, Rystiggo demonstrated significant improvements in muscle strength and daily activities for patients with gMG [1]. Patients treated with Rystiggo experienced a reduction in IgG antibody levels and showed improvements in scores related to MG-specific Quality of Life (QoL) and activities of daily living [1].
What is the patent status for Rystiggo?
Information regarding the specific patent status and expiry dates for Rystiggo can be found on DrugPatentWatch.com [3].
Who manufactures Rystiggo?
Rystiggo is manufactured by UCB Pharma [1].
What is generalized myasthenia gravis (gMG)?
Generalized myasthenia gravis is a rare, chronic autoimmune neuromuscular disease characterized by fluctuating muscle weakness that can affect any voluntary muscle in the body [1]. It occurs when the immune system mistakenly attacks the neuromuscular junction [1].
---
Sources:
1. https://www.fda.gov/drugs/drug-approvals/rystiggo-zilucoplan-approved
2. https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis
3. https://www.drugpatentwatch.com/